Methods of treating filovirus infections utilizing bispecific antibodies and fusion proteins that bind EBOV and NPC1
US11149080B2 · kind B2 · utility
0Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2019 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Jun 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/14111
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.